Physician profile
Aric Michael King
NPI 1871152975
$4,754.41
in general payments reported to CMS, 2019-2025
29 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.90 · 2021: $136 · 2022: $533 · 2023: $1,318 · 2024: $1,315 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,069.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $829.36 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $653.02 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $492.73 | 2022-2025 | |
| Lilly USA, LLC | $377.52 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.20 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $317.65 | 2024-2025 | Auvelity |
| Amgen INC. | $255.82 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $166.47 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $138.11 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $135.85 | 2023 | Quviviq |
| Hydrocision, INC. | $130.08 | 2025 | Tenjet |
| Novartis Pharmaceuticals Corporation | $112.83 | 2022-2024 | |
| Dexcom, INC. | $87.63 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $85.53 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $74.49 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $69.83 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.81 | 2023-2025 | Jardiance, Ofev |
| Dynavax Technologies Corporation | $59.21 | 2023-2024 | Heplisav-B |
| Astellas Pharma US INC | $52.58 | 2022-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $46.22 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $42.83 | 2024-2025 | Voquezna |
| Corium, LLC | $41.39 | 2024-2025 | Azstarys |
| Lundbeck LLC | $37.96 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $34.88 | 2022-2023 | Unithroid |
| Antares Pharma, INC. | $33.56 | 2025 | Xyosted |
| Boston Scientific Corporation | $29.98 | 2025 | Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $22.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.10 | 2022 | |
| Gilead Sciences, INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aric King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.